HofferA., OsmondH., SmythiesJ.R.Schizophrenia. A new approach. Part II. J Ment Sci1954; 100: 29–45.
2.
GrofS.Clinical and experimental study of central effects of adrenochrome. J Neuropsychiat1963; 5: 33–50.
3.
SchwarzB.E., Sem-JacobsenC., PetersenM.C.Effects of mescaline, LSD-25 and adrenochrome on depth electrograms in man. Arch Neuro] Psychiat1956; 75: 579–87.
4.
TaubmanG., JantzH.Untersuchung über die dem adrenochrom zugeschrieben psychotoxischen Wirkungen. Nervenartz1957; 28: 485–8.
HastingsT.G.Enzymatic oxidation of dopamine: the role of prostaglandin H synthetase. J Neurochem1995; 64: 919–24.
13.
MattammalM.B., StrongR., LakshuriV.M., ChungH.D., StephensonA.H.Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J Neurochem1995; 64: 1645–54.
14.
GeigerR.Effects of LSD-25, serotonin and sera from schizophrenics on adult mammalian brain cultures. J Neuropsychiat1960; 1: 185–99.
15.
EnochsW.S., SarnaT., ZeccaL., RileyP.A., SwartzH.M.The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J Neurotrans [P-D section]1994; 7: 83–100.
16.
GareyL.J., OngU.Y., PatelT.S.Reduction in dendritic spine number on cortical neurons in schizophrenia. Abst Soc Neurosci1995; 21: 236
17.
GlantzL.A., LewisD.A.Assessment of spine density on layer III pyramidal cells in the prefrontal cortex of schizophrenic subjects. Abst Soc Neurosci1995; 21: 237
18.
AkilM., LewisD.A.The catecholaminergic innervation of the human entorhinal cortex: alteration in schizophrenia. Abstr Soc Neurosci1995; 21: 238
19.
FillouxF., TownsendJ.J.Pre- and post-synaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol1993; 119: 79–88.
20.
AvocaP., SolanoF., SalinasC., García-BorrónJ.C., LozanoJ.A.Regulation of the final phase of mammalian melanogenesis. Eur J Biochem1992; 208: 155–63.
21.
SmitN.P.M., PavelS., KammayerA., WesterhofW.Determination of catechol O-methyltransferase activity in relation to melanin metabolism using high-performance liquid chromatography with fluorimetric detection. Anal Biochem1990; 190: 286–91; and see also Nicolaus RA. Melanins. Paris: Herman, 1968.
22.
KelsoeJ.R.Jr., TolbertL.C., CrewsE.L., SmythiesJ.R.Kinetic evidence for decreased methionine adenosyltransferase activity in erythrocytes from schizophrenics. J Neurosci Res1982; 8: 99–103.
23.
ReglandB., JohanssonB.V., GrenfeldtB., HjelmgrenL.T., MedhusM.Homocysteinemia is a common feature of schizophrenia, J Neural Transm [Gen Sect]1995; 100: 1391–8.
24.
SargentTIII, KusubovN., TaylorS.E., BudingerT.F.Tracer kinetic evidence for abnormal methyl metabolism in schizophrenia. Biol Psychiatr1992; 32: 1078–90.
25.
CarlssonA., WatersN., HanssonL.O.Neurotransmitter aberrations in schizophrenia: new findings. In: FogR, GerlachJ, HemmingsenR, eds. Schizophrenia. An Integrated View. Proceedings of a symposium held at the Royal Danish Academy of Sciences and Letters, 5-9 June 1994.
26.
SmythiesJ.On the function of neuromelanin. Proc R Soc B1996; 263: 987–989.